首页> 美国卫生研究院文献>Annals of Clinical Microbiology and Antimicrobials >30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient
【2h】

30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient

机译:30年病程尽管非免疫抑制的患者有多个转移器官参与但肺泡棘球co病的良好结局

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report the 30-yr history of a well-documented human case of alveolar echinococcosis, with a lung lesion at presentation followed by the discovery of a liver lesion, both removed by surgery. Subsequently, within the 13 years following diagnosis, metastases were disclosed in eye, brain and skull, as well as additional lung lesions. This patient had no immune suppression, and did not have the genetic background known to predispose to severe alveolar echinococcosis; it may thus be hypothesized that iterative multi-organ involvement was mostly due to the poor adherence to benzimidazole treatment for the first decade after diagnosis. Conversely, after a new alveolar echinococcosis recurrence was found in the right lung in 1994, the patient accepted to take albendazole continuously at the right dosage. After serology became negative and a fluoro-deoxy-glucose-Positron Emission Tomography performed in 2005 showed a total regression of the lesions in all organs, albendazole treatment could be definitively withdrawn. In 2011, the fluoro-deoxy-glucose-Positron Emission Tomography showed a total absence of parasitic metabolic activity and the patient had no clinical symptoms related to alveolar echinococcosis.The history of this patient suggests that multi-organ involvement and alveolar echinococcosis recurrence over time may occur in non-immune suppressed patients despite an apparently “radical” surgery. Metastatic dissemination might be favored by a poor adherence to chemotherapy. Combined surgery and continuous administration of albendazole at high dosage may allow alveolar echinococcosis patients to survive more than 30 years after diagnosis despite multi-organ involvement.
机译:我们报告了一个有充分记录的人类肺泡棘球cc病病例的30年历史,患者在出现肺部病变后发现了肝脏病变,两者均通过手术切除。随后,在诊断后的13年内,发现眼,脑和颅骨转移以及其他肺部病变。该患者没有免疫抑制作用,也没有已知的易患严重肺泡棘球co病的遗传背景。因此,可以假设反复的多器官参与主要是由于诊断后最初十年对苯并咪唑的依从性差。相反,1994年在右肺发现了新的肺泡棘球co病复发后,患者接受了以正确剂量连续服用阿苯达唑。血清学检查阴性后,2005年进行的氟脱氧葡萄糖正电子发射断层扫描显示所有器官的病变完全消退,可以最终撤消阿苯达唑治疗。 2011年,氟脱氧葡萄糖正电子发射断层扫描显示完全没有寄生代谢活动,患者没有与肺泡棘球al虫病相关的临床症状,该患者的病史表明随着时间的推移多器官受累和肺泡棘球ech虫病复发。尽管有明显的“根治性”手术,但仍可能发生在非免疫抑制患者中。对化疗的依从性差可能有助于转移性传播。尽管有多器官累及,但结合手术和高剂量阿苯达唑的连续给药可以使肺泡棘球osis虫病患者在诊断后存活30多年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号